| Name | Title | Contact Details |
|---|---|---|
Marilu Soriano-Tilley |
VP, HR Business Partner | Profile |
Jeffrey Tratner |
Senior Director of Software Engineering - R&D Platform | Profile |
Andria Del Tredici |
R&D Senior Product Director, Mental Health | Profile |
Summer Pierson |
R&D Product Director: Clinical Research | Profile |
Jeff Jasper |
Oncology R&D Product Director | Profile |
HomeDNA, Inc. is a Keller, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. The company is advancing a broad, diversified pipeline of multiple, selective small molecule therapeutics for highly sought-after disease-causing target proteins in oncology and immunology. The company`s cutting-edge platform was spun out of the labs of Vividion`s scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA.
CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea.
Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage`s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage`s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer.